Partnerships, Licensing, Investments and M&A Deals and Trends for February 2020 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2020 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents

1. Table of Contents 2

1.1. List of Tables 5

1.2. List of Figures 7

2. Deal Values in Pharmaceutical and Healthcare Industry Has Decreased in February2020 9

2.1. Pharmaceuticals & Healthcare, Deals Summary, February 2020 9

3. Pharmaceuticals & Healthcare, Global, Deal Summary, 13

3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2020 13

3.2. Pharmaceuticals & Healthcare, Global, Major Deals, February 2020 14

3.2.1. Amgen Raises USD5 Billion in Debt Offering of Senior Unsecured Notes 15

3.2.2. Novartis Prices Public Offering of Notes for USD5 Billion 15

3.2.3. Biogen and Sangamo Therapeutics to Enter into Licensing Agreement 15

3.2.4. Genentech Enters into Licensing Agreement with Bicycle Therapeutics 16

3.2.5. Exact Sciences Prices Public Offering of

0.3750% Notes Due 2028 for USD1 Billion 17

3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 2020 18

3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 2020 19

4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20

4.1. Pharmaceuticals & Healthcare, Global, M&A, February 2020 20

4.1.1. Top M&A Deals in February 2020 21

4.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2019– February 2020 22

4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2020 23

4.2.1. Top Equity Offering Deals in February 2020 24

4.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2019– February 2020 25

4.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2020 26

4.3.1. Top PE/VC Deals in February 2020 27

4.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 2020 28

4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2020 30

4.3.5. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, September 2019–February 2020 32

4.3.7. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2019–February 2020 33

4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2020 34

4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2019– February 2020 35

4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2020 36

4.6.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 2020 37

4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2019– February 2020 38

4.8. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2019– February 2020 40

4.9. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2019– February 2020 41

4.10. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2019– February 2020 43

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2020 45

5.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2020 45

5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2020 47

5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2019– February 2020 49

5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2019– February 2020 51

5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2019– February 2020 53

5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2019– February 2020 56

5.6.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 2020 57

5.6.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 2020 58

5.6.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2020 59

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 60

6.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2020 60

6.1.1. Oncology – Deals of the Month 61

6.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2020 63

6.2.1. Central Nervous System – Deals of the Month 64

6.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2020 66

6.3.1. Infectious Diseases – Deals of the Month 67

6.4. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2020 69

6.4.1. Cardiovascular – Deals of the Month 70

6.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2020 72

6.5.1. Immunology – Deal of the Month 73

6.6. Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, February 2020 75

6.6.1. Metabolic– Deals of the Month 76

6.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, February 2020 78

6.7.1. Gastrointestinal – Deals of the Month 79

7. Deal Summary by Geography 81

7.1. Pharmaceuticals & Healthcare, North America Deals, February 2020 81

7.1.1. North America – Deals of the Month 82

7.2. Pharmaceuticals & Healthcare, Europe, Deals, February 2020 85

7.2.1. Europe – Deals of the Month 86

7.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2020 88

7.3.1. Asia-Pacific – Deals of the Month 89

7.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2020 90

7.4.1. Rest of the World – Deals of the Month 91

8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors 93

8.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2019– February 2020 93

8.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2019– February 2020 95

9. Further Information 97

9.1. Methodology 97

9.2. About GlobalData 98

9.3. Contact Us 98

9.4. Disclosure information 98

9.5. Disclaimer 98

List of Tables

1.1. List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 14

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, February 2020 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 2020 19

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 2020 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2019– February 2020 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 24

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 2020 24

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 25

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 27

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 2020 27

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2019– February 2020 28

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), February 2020 31

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2019– February 2020 32

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2019– February 2020 33

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2019– February 2020 34

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2019– February 2020 35

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2019– February 2020 36

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 2020 37

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2019– February 2020 39

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2019– February 2020 42

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2019– February 2020 44

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 46

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2019– February 2020 48

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2019– February 2020 50

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 2020 52

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, September 2019– February 2020 55

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2020 57

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, February 2020 57

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 2020 58

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 2020 59

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 61

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 64

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 67

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 70

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 73

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 76

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 79

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 82

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 86

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 89

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 91

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2019– February 2020 94

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2019– February 2020 96

List of Figures

1.2. List of Figures

Figure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, February 2020 9

Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, September 2019 – February 2020 10

Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, February 2020 11

Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, February 2020 12

Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2019– February 2020 13

Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), February 2020 18

Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), February 2020 19

Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), September 2019– February 2020 20

Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2019– February 2020 22

Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2019– February 2020 23

Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2019– February 2020 25

Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2019– February 2020 26

Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2019– February 2020 28

Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), February 2020 30

Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), February 2020 31

Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2019– February 2020 32

Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2019– February 2020 34

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2019– February 2020 35

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2019– February 2020 36

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2019– February 2020 38

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2019– February 2020 40

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2019– February 2020 41

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2019– February 2020 43

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2019– February 2020 45

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2019– February 2020 47

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2019– February 2020 49

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2019– February 2020 51

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, September 2019– February 2020 53

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), September 2019– February 2020 54

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 2020 56

Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2019– February 2020 60

Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2019– February 2020 63

Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2019– February 2020 66

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2019– February 2020 69

Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2019– February 2020 72

Figure 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 75

Figure 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2019– February 2020 78

Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2019– February 2020 81

Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2019– February 2020 85

Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2019– February 2020 88

Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2019– February 2020 90

Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2019– February 2020 93

Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2019– February 2020 95

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports